What is Maculacare?
Established in 1998, MaculaCare operates as a premier medical group dedicated to the diagnosis and surgical management of complex ocular conditions. The practice specializes in high-acuity care for patients suffering from dry age-related macular degeneration, diabetic retinopathy, and retinal detachment. Through a combination of cutting-edge diagnostic technology and a highly skilled team of ophthalmologists, the company has established a reputation for excellence in patient outcomes. With three strategic locations across New York City, MaculaCare bridges the gap between academic-level research and accessible community-based healthcare, maintaining a broad patient reach through comprehensive insurance acceptance, including Medicare.
How much funding has Maculacare raised?
Maculacare has raised a total of $380K across 2 funding rounds:
Debt
$150K
Debt
$230K
Debt (2020): $150K with participation from PPP
Debt (2021): $230K led by PPP
Key Investors in Maculacare
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Maculacare?
With the infusion of this latest capital, MaculaCare is well-positioned to accelerate its growth trajectory and enhance its clinical infrastructure. The organization is expected to prioritize the integration of next-generation surgical equipment and expand its research initiatives, which are critical for maintaining its competitive advantage in the ophthalmology sector. As the company navigates this late-stage growth phase, the focus will likely shift toward optimizing operational efficiencies across its existing clinics and potentially exploring further geographic expansion. By maintaining its commitment to specialized care, MaculaCare is poised to capture a larger share of the growing demand for advanced retinal health services, ensuring long-term sustainability and continued leadership in the specialty eye care market.
See full Maculacare company page
